Promising Clinical Trial Results and Strategic Advancements Justify Buy Rating for Faron Pharmaceuticals

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Faron Pharmaceuticals Oy today and set a price target of £10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors including promising clinical trial results and strategic advancements. The updated Phase 1/2 trial data presented at the ASH 2025 Annual Meeting demonstrated a significant improvement in survival rates for patients with high-risk myelodysplastic syndrome (HR-MDS) when treated with Faron’s monoclonal antibody, bexmarilimab, in combination with azacitidine. Notably, the combination therapy achieved a 64% objective response rate and extended median overall survival to 14.5 months in patients who had previously failed hypomethylating agent treatments.
Furthermore, the therapy showed remarkable efficacy in treatment-naïve HR-MDS patients with TP53 mutations, achieving a complete remission rate of 70%, significantly higher than standard treatments. These results position bexmarilimab as a promising late-stage immunotherapy, supporting Faron’s strategy to advance to a Phase 2/3 registrational program with potential for accelerated approval. The valuation of Faron Pharmaceuticals is supported by a risk-adjusted methodology, considering various probabilities of success across different tumor types and employing a discount rate of 12%. Despite potential risks such as clinical development and commercialization challenges, the positive trial outcomes and strategic direction justify the Buy rating and a price target of £10.